Sponsors educational summit of leading pediatric AKI health care experts
Announces best practices webinar to further advance new treatment options
DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that it is a proud sponsor of key initiatives to advance the treatment of pediatric patients with acute kidney injury (AKI). AKI is a major driver of critical illness, prolonged hospital stays, and high mortality rates. Despite its massive impact on patient outcomes, significant gaps in awareness and clinical protocol persist, particularly within pediatric medicine.
"We are committed to working hand-in-hand with the pediatric acute care community to ensure that every child in the ICU suffering from severe AKI receives the latest, most innovative treatments," stated Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. "The current reality is that more than 50% of these children lose their life to this complication of their acute illness. We are committed to helping give these patients a chance."
SeaStar Medical is sponsoring and participating in the KidneyBee Summit 2026 that takes place at Children's Hospital Colorado from July 14 to 16, 2026. The Summit is a highly specialized, interdisciplinary conference that brings together nurses, advanced practice providers, and physicians from across the country. Its core importance stems from tackling the exact systemic failures that leave pediatric kidney failure under-recognized.
SeaStar Medical is also sponsoring an educational webinar designed to discuss improving outcomes for critically ill children. The webinar will focus on the use of SeaStar Medical's QUELIMMUNE® (SCD-PED) therapy, a first-in-class treatment designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient's body.
The educational seminar, entitled Rethinking Pediatric Sepsis-Associated AKI: What Clinicians Should Know About QUELIMMUNE, will occur on August 11, 2026, from 12:00 to 1:00 pm Eastern Time. Practicing pediatric nephrologists, critical care physicians, advanced practice providers, nurses, and critical care teams are invited to join the seminar to learn more about pediatric sepsis-associated AKI and the use of the QUELIMMUNE therapy. Additional details are below: